Malmanu, this is a most valuable article - thank you. My initial...

Malmanu, this is a most valuable article - thank you. My initial answer to your question is that this could be a good thing for OSL once the effectiveness of OSL's treatment is proven. There is presently no cure for pancreatic cancer. OSL's treatment is a targeted treatment and potential cure. The early identification of the cancer should mean that the earlier application of OSL's treatment should have greater effectiveness. Hopefully, the earlier application of OSL's treatment could mean it can become a complete cure. My other observation is that it could mean the market for OSL's product is much larger than one currently assumes now. A simple (and cost-effective?) way to identify pancreatic cancer should mean that it becomes standard in blood tests and more people throughout the world with the disease can be identified, meaning a bigger target market for OSL. The key points about OSL remain: 1. That it prove its treatment works and 2. That it do so as quickly as possible (going to the question of cash burn). If OSL can secure CE Mark approval soon it can commercialize the treatment immediately, thereby hopefully bringing in revenues, and making the need for a potential capital raising unnecessary. This seems to me a legitimate expectation, but of course, management has to make that happen. My research leads me to believe that OSL has a world-class technology. I do not believe this is recognized by the market nor is it being reflected in the share price. But, that's the market isn't it and management has to prove its case.